80
Participants
Start Date
October 31, 2011
Primary Completion Date
March 31, 2013
Study Completion Date
March 31, 2016
Obinutuzumab
Participants were administered obinutuzumab either at 1000 mg or 2000 mg on Day 1, 8, 15 of Cycle 1 and then on Day 1 of each 21 day cycles for up to 8 cycles.
Corticosteroids
Participants were administered corticosteroids IV prior to the initial dose.
Columbia University Medical Center, New York
Virginia Cancer Specialists, PC, Fairfax
Shenandoah Oncology Associates, Winchester
SW Virginia Hem Onc, Roanoke
Purchase Cancer Group, Paducah
Ohio State University, Columbus
Mark H. Zangmeister Center, Columbus
Kettering Medical Center, Kettering
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
Goshen Hlth Sys Ctr Can Care, Goshen
Horizon Oncology Research, Inc., Lafayette
INTEGRIS Cancer Inst of OK, Oklahoma City
Texas Oncology-Medical City Dallas, Dallas
Texas Oncology - Dallas Presbyterian Hospital, Dallas
US Oncology Research Pharm., Fort Worth
Univ of Colorado Canc Ctr, Aurora
Rocky Mountain Cancer Center; Medical Oncology, Denver
Kootenai Cancer Center, Post Falls
Arizona Oncology, Tucson
Arizona Clinical Research Ctr, Tucson
USC Norris Cancer Center, Los Angeles
USC/Norris Can Ctr; IDS Pharm, Los Angeles
Wilshire Oncology Medical Group, Pasadena
University of California; Moores Cancer Center, La Jolla
Ventura County Hematology-Oncology Specialists, Oxnard
Northwest Cancer Specialists - Vancouver, Vancouver
Yakima Valley Memorial Hospital/North Star Lodge, Yakima
Univ of Alabama at Birmingham; UAB Comprehensive Cancer Ctr, Birmingham
Hem Onc Assoc of Northern NJ; Carol G. Simon Canc Ctr, Morristown
Willamette Valley Cancer Ctr - 520 Country Club, Eugene
Texas Cancer Center - Sherman, Sherman
Lead Sponsor
Genentech, Inc.
INDUSTRY